According to the Legislative Budget Board (LBB), SB 1098 is not expected to have a significant fiscal impact on the state of Texas. The LBB notes that any costs associated with implementing the provisions of the bill—such as pharmacies disclosing lower drug prices to patients—can be absorbed within existing resources. This suggests that the state agencies involved, particularly the Texas State Board of Pharmacy, do not foresee the need for additional funding, staffing, or infrastructure to comply with or enforce the bill's requirements.

For local governments, the fiscal impact is also deemed negligible. No significant costs are anticipated for local entities, which aligns with the bill's scope as it imposes obligations solely on private-sector pharmacies rather than governmental units. The streamlined nature of the bill, focused only on requiring existing pricing information to be communicated to patients, limits administrative overhead or new regulatory burdens that would typically incur public costs.

In summary, SB 1098 presents a consumer transparency reform that achieves its policy goals without creating substantial financial demands on state or local government resources.

SB 1098 is a targeted consumer protection measure that empowers patients through greater transparency in prescription drug pricing. As outlined in the bill analysis, the legislation responds directly to a persistent issue: co-payment overcharges at the pharmacy counter. Studies cited in the analysis—particularly data from the Journal of the American Medical Association—demonstrate that up to 28 percent of generic prescriptions involve patients overpaying relative to the drug's actual cost, with insurers or pharmacy benefit managers pocketing the difference. SB 1098 addresses this by requiring pharmacists to disclose the lowest cash price for a prescribed drug or biological product, enabling patients to choose the more affordable option.

The policy rationale behind the bill aligns well with the principles of personal responsibility and individual liberty, allowing patients to make informed financial and healthcare decisions. It is also market-friendly, encouraging fair competition and discouraging opaque pricing schemes. From a fiscal standpoint, as confirmed by the Legislative Budget Board, the bill imposes no significant cost to the state or local governments, and any compliance costs can be absorbed by existing resources.

Importantly, SB 1098 does not authorize new rulemaking power or expand the scope of state government beyond a simple, clearly defined disclosure requirement. It avoids unnecessary bureaucracy while producing tangible benefits to consumers, particularly seniors and low-income patients who are most affected by high drug costs. For these reasons, Texas Policy Research recommends that lawmakers vote YES on SB 1098.

• Individual Liberty: The bill directly enhances individual liberty by giving patients access to critical pricing information that affects their healthcare choices. When patients are informed that the cash price for a medication is cheaper than their insurance co-pay, they gain the autonomy to make the most cost-effective decision for themselves. This respects and strengthens the individual's right to make informed decisions free from hidden or coercive practices by insurers or pharmacy benefit managers.
• Personal Responsibility: By requiring pharmacies to disclose the lowest available cash price, SB 1098 supports individuals in taking greater responsibility for managing their healthcare expenditures. Patients can weigh their options and select the payment method that best fits their financial situation, promoting proactive consumer behavior in navigating the healthcare market.
• Free Enterprise: The bill promotes fair market principles by reducing information asymmetry in the pharmaceutical retail space. When consumers are informed about pricing alternatives, pharmacies and insurance entities are incentivized to offer competitive pricing. This fosters a healthier, more transparent marketplace where price competition is driven by consumer choice, not contractual concealment.
• Private Property Rights: The bill does not infringe upon private property or contractual rights. Pharmacies retain full discretion over how they price their products. The only obligation is to disclose an existing price point—the lowest cash price—which the pharmacy already sets. This light-touch regulatory measure respects private business operations while ensuring ethical disclosure practices.
• Limited Government: The legislation achieves its objectives without expanding regulatory agencies or granting new rulemaking authority. It imposes a single, clear obligation on pharmacies, avoiding bureaucratic complexity or large-scale administrative oversight. By solving a significant consumer protection issue through minimal state intervention, the bill exemplifies the principle of limited government action with maximum public benefit.